Recursion Pharmaceuticals Inc RXRX

RXRX RELEASE OPENPHENOM-S/16 IN GOOGLE CLOUDS NOV 12

[Humanist]

Recursion Announces the Release of OpenPhenom-S/16 in Google Cloud’s Model Garden
Recursion Pharmaceuticals, Inc.

Tue, November 12, 2024 at 4:54 PM EST 6 min read

RXRX
-3.43%

Recursion Pharmaceuticals, Inc.
OpenPhenom is a non-commercial, publicly available foundation model built on microscopy data that has set the new "gold standard" outperforming CellProfiler

SALT LAKE CITY, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, announced today the release of OpenPhenom-S/16, a publicly available foundation model in Google Cloud’s Vertex AI Model Garden. This will enable Life Science companies to use OpenPhenom-S/16 on Google Cloud when building apps that require microscopy data to assess the effectiveness of drug treatments, analyze cultures, study tissues and ultimately accelerate drug discovery and for other uses.
“We are thrilled to announce that Recursion is setting a new gold standard for the industry with the release of OpenPhenom-S/16, a foundation model for microscopy data trained using masked-autoencoder-based self-supervised learning on more than three million microscopy images from publicly accessible datasets (RxRx3 and JUMP-CP),” said Ben Mabey, chief technology officer at Recursion.

Large-scale cell microscopy assays have become instrumental in unveiling novel biological processes, potential drug candidates, and targets. Traditionally, laboratories have relied on legacy image segmentation and feature extraction software packages that need to be tuned for each new assay and are often brittle to minor changes in assay conditions. With the increasing scale and complexity of private and public datasets, such as RxRx3 and JUMP-CP, these existing software packages and associated downstream analysis methods struggle to handle the sheer volume of data effectively.

OpenPhenom-S/16 will allow non-commercial researchers to potentially replace their existing workflows with this off-the-shelf model that outperforms traditional microscopy analysis pipelines without requiring any additional tuning or training. For example, with OpenPhenom-S/16, Recursion presents an unprecedented improvement in recalling known biological relationships from the StringDB database in the public JUMP-CP cpg0016 dataset.

Figure 1 demonstrates the improvement in recalling known biological relationships (PLoS Comp Bio 2024) from the StringDB database in the public JUMP-C
 
Figure 1 demonstrates the improvement in recalling known biological relationships (PLoS Comp Bio 2024) from the StringDB database in the public JUMP-CP dataset when using OpenPhenom-S/16 embeddings compared to the gold standard approach with CellProfiler.
 
"We’re pleased Recursion is bringing OpenPhenom-S/16 to the life science community through Google Cloud's Vertex AI Model Garden,” said Shweta Maniar, global director of Life Science Strategy & Solutions, Google Cloud. “This powerful foundation model, combined with the scalability and accessibility of our Vertex AI platform, has the potential to accelerate microscopy analysis by automating classification of cellular structures, detecting patterns and anomalies, and extracting valuable insights from complex microscopy data. By democratizing access to this cutting-edge technology, Recursion will empower researchers around the globe to make new discoveries and advance the field of biomedicine."

As a leader in this space, Recursion also has models for commercial use for its own pipeline and partnership programs. Recursion has featured the performance of two generations of proprietary models trained on Recursion’s internal microscopy, Phenom-1 (CVPR 2024) and Phenom-2 (NeurIPS FM4S 2024).

To accompany OpenPhenom-S/16, Recursion is releasing the RxRx3-core dataset, a challenge dataset in phenomics optimized for the research community. RxRx3-core includes labeled images of 735 genetic knockouts and 1,674 small-molecule perturbations drawn from the RxRx3 dataset, image embeddings computed with OpenPhenom-S/16, and associations between the included small molecules and genes. “Mapping the mechanisms by which drugs exert their actions is an important challenge in advancing the use of high-dimensional biological data like phenomics. We are excited to release the first dataset of this scale probing concentration-response along with a benchmark and model to enable the research community to rapidly advance this space,” commented Imran Haque, Ph.D., SVP of AI and Digital Sciences at Recursion.
 
To access OpenPhenom-S/16 on Google Cloud, through Hugging Face, please visit RxRx.ai/phenom. For more details on RxRx3-core, find the dataset at https://rxrx.ai/rxrx3-core. Please sign up at RxRx.ai to receive updates on all data and model releases from Recursion.
 
About Recursion
Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest proprietary biological and chemical datasets. Recursion leverages sophisticated machine-learning algorithms to distill from its dataset a collection of trillions of searchable relationships across biology and chemistry unconstrained by human bias. By commanding massive experimental scale — up to millions of wet lab experiments weekly — and massive computational scale — owning and operating one of the most powerful supercomputers in the world, Recursion is uniting technology, biology and chemistry to advance the future of medicine.

Recursion is headquartered in Salt Lake City, where it is a founding member of BioHive, the Utah life sciences industry collective. Recursion also has offices in Toronto, Montral, London, and the San Francisco Bay Area. Learn more at www.Recursion.com, or connect on X (formerly Twitter) and LinkedIn.
Media Contact
[e-mail]
Investor Contact
[e-mail]